Tempus AI shares saw a transaction-level data point after its CEO, Ryan Fukushima, reported the sale of 41,095 shares of common stock on August 18, according to a recent U.S. Securities and Exchange Commission filing. The disposals were executed at a weighted average price of $49.61 per share, for about $2.0 million in proceeds, as part of a tax-withholding arrangement tied to restricted stock unit vesting.
While the trade itself was non-discretionary, the filing also underscores that Fukushima remains a significant shareholder after the sale, with roughly 624,000 shares in total ownership following the transaction, including shares held indirectly by his spouse.
Key takeaways
- Price move: Fukushima sold 41,095 shares at a weighted average of $49.61 per share, alongside the market close value referenced in the filing of $49.36.
- Catalyst: The sale was a non-discretionary “sell to cover” to meet statutory tax withholding requirements triggered by the vesting of restricted stock units.
- Remaining stake: Post-sale, Fukushima held about 624,169 shares in total (562,463 direct and 61,706 indirect).
- Implication: Investors typically treat sell-to-cover activity as administrative rather than a change in investment thesis, though persistent insider selling can still be monitored alongside company fundamentals.
What drove the share disposition
According to the SEC Form 4 filing, the transaction was structured as a non-discretionary “sell to cover” event. The company’s CEO executed the sale to satisfy statutory tax withholding obligations that arise when restricted stock units vest. As the filing frames it, the disposition does not reflect an insider decision based on a view of the stock.
For reference, the filing indicates the weighted average sale price was $49.61 per share, resulting in an estimated transaction value of about $2.0 million. It also cites a post-transaction share value based on the stock’s August 18 close price of $49.36.
How much the CEO sold—and what remains
Data from the SEC filing shows Fukushima reduced his holdings by 41,095 shares. After the transaction, his total ownership stood at 624,169 shares, consisting of:
- 562,463 shares held directly
- 61,706 shares held indirectly by his spouse
Because the sale was tied to RSU vesting and tax requirements, the size of the reduction is best interpreted as the operational mechanics of compensation rather than a broad liquidation of the CEO’s position.
Market context and what investors will watch
In addition to the insider transaction, Tempus AI’s broader stock performance and narrative have been influenced by company-specific catalysts reported in the market. The same period included news related to Tempus’s trial activity and a revaluation of a pending Personalis deal, which was followed by a sharp one-day stock move. That kind of reaction can matter for investors because it can quickly shift expectations around the company’s commercial timeline, partnerships, and pipeline relevance—factors that may also influence how shareholders interpret insider activity.
Still, insider “sell to cover” transactions often occur even during periods of positive market sentiment, since they are triggered by routine vesting schedules. The primary takeaway from the filing, therefore, is not a directional statement by management, but rather the continued scale of Fukushima’s ownership after the sale.
Financially, Tempus AI reported a market capitalization of $10.7 billion as of the August 19 market close and posted trailing twelve-month revenue of $1.4 billion, along with a trailing twelve-month net loss of $254.4 million, based on the figures presented alongside the filing context. The company remains in a growth investment phase, where revenue expansion and unit economics are key monitoring points for investors.
Bigger picture for Tempus AI
Tempus AI operates a healthcare technology platform that connects clinician workflows with laboratory diagnostics, advanced analytics, and a multimodal data repository used for precision medicine applications. The company’s model centers on products and services that aim to support data-driven clinical decision-making, serving physicians, healthcare providers, and clinical laboratories with emphasis on oncology and precision medicine use cases.
For shareholders, the insider filing serves as a reminder to separate administrative insider transactions from signals about long-term conviction. The more durable question is whether Tempus’s platform momentum continues to translate into sustainable operating progress, especially given its current profitability profile.
Looking ahead, investors will likely focus on the next set of company updates that can clarify growth trajectory—such as subsequent quarterly results, updates on data and application licensing momentum, and any developments tied to diagnostics partnerships and trial-related catalysts. In the near term, market attention may also remain sensitive to broader biotech and healthcare sentiment, including how investors weigh deal milestones and clinical validation against the company’s path to improved margins.
